Skip to main content
Journal cover image

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

Publication ,  Journal Article
Kulasingam, S; Connelly, L; Conway, E; Hocking, JS; Myers, E; Regan, DG; Roder, D; Ross, J; Wain, G
Published in: Sex Health
September 2007

BACKGROUND: The cost-effectiveness of adding a human papillomavirus (HPV) vaccine to the Australian National Cervical Screening Program compared to screening alone was examined. METHODS: A Markov model of the natural history of HPV infection that incorporates screening and vaccination was developed. A vaccine that prevents 100% of HPV 16/18-associated disease, with a lifetime duration of efficacy and 80% coverage offered through a school program to girls aged 12 years, in conjunction with current screening was compared with screening alone using cost (in Australian dollars) per life-year (LY) saved and quality-adjusted life-year (QALY) saved. Sensitivity analyses included determining the cost-effectiveness of offering a catch-up vaccination program to 14-26-year-olds and accounting for the benefits of herd immunity. RESULTS: Vaccination with screening compared with screening alone was associated with an incremental cost-effectiveness ratio (ICER) of $51 103 per LY and $18 735 per QALY, assuming a cost per vaccine dose of $115. Results were sensitive to assumptions about the duration of vaccine efficacy, including the need for a booster ($68 158 per LY and $24 988 per QALY) to produce lifetime immunity. Accounting for herd immunity resulted in a more attractive ICER ($36 343 per LY and $13 316 per QALY) for girls only. The cost per LY of vaccinating boys and girls was $92 052 and the cost per QALY was $33 644. The cost per LY of implementing a catch-up vaccination program ranged from $45 652 ($16 727 per QALY) for extending vaccination to 14-year-olds to $78 702 ($34 536 per QALY) for 26-year-olds. CONCLUSIONS: These results suggest that adding an HPV vaccine to Australia's current screening regimen is a potentially cost-effective way to reduce cervical cancer and the clinical interventions that are currently associated with its prevention via screening alone.

Duke Scholars

Published In

Sex Health

DOI

ISSN

1448-5028

Publication Date

September 2007

Volume

4

Issue

3

Start / End Page

165 / 175

Location

Australia

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Quality-Adjusted Life Years
  • Quality of Life
  • Public Health
  • Papillomavirus Vaccines
  • Papillomavirus Infections
  • National Health Programs
  • Mass Vaccination
  • Markov Chains
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kulasingam, S., Connelly, L., Conway, E., Hocking, J. S., Myers, E., Regan, D. G., … Wain, G. (2007). A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health, 4(3), 165–175. https://doi.org/10.1071/sh07043
Kulasingam, Shalini, Luke Connelly, Elizabeth Conway, Jane S. Hocking, Evan Myers, David G. Regan, David Roder, Jayne Ross, and Gerard Wain. “A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.Sex Health 4, no. 3 (September 2007): 165–75. https://doi.org/10.1071/sh07043.
Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health. 2007 Sep;4(3):165–75.
Kulasingam, Shalini, et al. “A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.Sex Health, vol. 4, no. 3, Sept. 2007, pp. 165–75. Pubmed, doi:10.1071/sh07043.
Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health. 2007 Sep;4(3):165–175.
Journal cover image

Published In

Sex Health

DOI

ISSN

1448-5028

Publication Date

September 2007

Volume

4

Issue

3

Start / End Page

165 / 175

Location

Australia

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Quality-Adjusted Life Years
  • Quality of Life
  • Public Health
  • Papillomavirus Vaccines
  • Papillomavirus Infections
  • National Health Programs
  • Mass Vaccination
  • Markov Chains
  • Humans